The European Medicines Agency published new guidance on whether less comprehensive data can be used to support a new indication for a previously approved orphan drug product.
Source: International Pharmaceutical Regulatory Monitor
The European Medicines Agency published new guidance on whether less comprehensive data can be used to support a new indication for a previously approved orphan drug product.
Source: International Pharmaceutical Regulatory Monitor